Research Comparison
Mazdutide (IBI362 / LY3305677) vs Retatrutide (LY3437943)
A side-by-side research comparison of Mazdutide (IBI362 / LY3305677) and Retatrutide (LY3437943) drawn from Cobalt Peptides' peptide database records.
Mazdutide (IBI362 / LY3305677)
Mazdutide (IBI362 / LY3305677) is a synthetic analogue of oxyntomodulin acting as a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist. Unlike GLP-1-only or GIP/GLP-1 compounds, it engages the glucagon receptor as well, a mechanism examined in the published literature for its distinct contribution to energy balance. Mazdutide is not an approved medicine and remains in clinical development. Supplied strictly as a research compound for laboratory use.
Retatrutide (LY3437943)
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist with activity at the GLP-1, GIP and glucagon receptors. Its design combines incretin-axis signalling through GLP-1 and GIP with glucagon receptor activity, a combination studied for its effects on energy balance in published metabolic research. Retatrutide is not an approved medicine in the United Kingdom or elsewhere and remains in clinical development by its originator. Supplied strictly as a research compound for laboratory use.